<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618263</url>
  </required_header>
  <id_info>
    <org_study_id>GATE-101-C-101</org_study_id>
    <nct_id>NCT04618263</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers</brief_title>
  <official_title>A Randomized Double-blind, Placebo-controlled Single and Multiple Intravenous Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of GATE-101 in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gate Neurosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gate Neurosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending&#xD;
      doses of GATE-101 in normal human volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single ascending dose (SAD), multiple ascending dose (MAD), double-blind placebo-controlled&#xD;
      study in normal human volunteers.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To evaluate the pharmacokinetics (PK) of GATE-101 following increasing single and multiple&#xD;
      doses of intravenously (IV) administered GATE-101.&#xD;
&#xD;
      GATE-101 or Placebo: Dose/Mode of Administration: Single or 5 Daily Doses;Intravenous&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Triple, Participant, Investigator, Outcomes Assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events Through Study Completion, 28 days</measure>
    <time_frame>28 Days</time_frame>
    <description>Safety and Tolerabiity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - maximum plasma concentration - following a single intravenous dose</measure>
    <time_frame>72 hours</time_frame>
    <description>Maximum observed plasma concentration following a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - maximum plasma concentration - following 5 daily intravenous doses</measure>
    <time_frame>72 hours</time_frame>
    <description>Maximum observed plasma concentration following the fifth daily doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - area under the curve - following a single intravenous dose</measure>
    <time_frame>72 hours</time_frame>
    <description>Area under the concentration time curve from time 0 to infinity following a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - area under the curve - following 5 daily intravenous doses</measure>
    <time_frame>72 hours</time_frame>
    <description>Area under the concentration time curve from time 0 to infinity following the fifth daily dose</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Excessive Sleepiness</condition>
  <arm_group>
    <arm_group_label>GATE-101, 5 mg IV, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101, 5 mg IV, Single Dose, with follow up of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101, 15 mg IV, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101, 15 mg IV, Single Dose, with follow up of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101, 50 mg IV, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101, 50 mg IV, Single Dose, with follow up of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101, 150 mg IV, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101, 150 mg IV, Single Dose, with follow up of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101, 450 mg IV, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101, 450 mg IV, Single Dose, with follow up of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101, 15 mg IV, Single Dose, Lumbar Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101, 50 mg IV, Single Dose, Lumbar Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101 5 mg IV, Five Daily Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101 15 mg IV, Five Daily Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GATE-101 150 mg IV, Five Daily Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator, Single Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator, Single Dose, with follow up for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator, Five Daily Doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GATE-101</intervention_name>
    <description>GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist</description>
    <arm_group_label>GATE-101 15 mg IV, Five Daily Doses</arm_group_label>
    <arm_group_label>GATE-101 150 mg IV, Five Daily Doses</arm_group_label>
    <arm_group_label>GATE-101 5 mg IV, Five Daily Doses</arm_group_label>
    <arm_group_label>GATE-101, 15 mg IV, Single Dose</arm_group_label>
    <arm_group_label>GATE-101, 15 mg IV, Single Dose, Lumbar Catheter</arm_group_label>
    <arm_group_label>GATE-101, 150 mg IV, Single Dose</arm_group_label>
    <arm_group_label>GATE-101, 450 mg IV, Single Dose</arm_group_label>
    <arm_group_label>GATE-101, 5 mg IV, Single Dose</arm_group_label>
    <arm_group_label>GATE-101, 50 mg IV, Single Dose</arm_group_label>
    <arm_group_label>GATE-101, 50 mg IV, Single Dose, Lumbar Catheter</arm_group_label>
    <arm_group_label>Placebo Comparator, Five Daily Doses</arm_group_label>
    <arm_group_label>Placebo Comparator, Single Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal, healthy volunteer male and female subjects&#xD;
&#xD;
          2. Aged 18 to 40 years&#xD;
&#xD;
          3. For female subjects must meet one of the following:&#xD;
&#xD;
               -  Surgically sterile or at least 2 years menopausal, confirmed by follicle&#xD;
                  stimulating hormone (FSH) at screening visit, or,&#xD;
&#xD;
               -  If of childbearing potential, subject must use an acceptable method of birth&#xD;
                  control from date of screening to at least 30 days after the last dose of study&#xD;
                  drug. Must have a documented negative blood or urine pregnancy test within 24&#xD;
                  hours prior to dosing. If reported sterile or postmenopausal, will be confirmed&#xD;
                  by FSH.&#xD;
&#xD;
          4. For male subjects, must meet one of the following:&#xD;
&#xD;
               -  Surgically sterile&#xD;
&#xD;
               -  If not surgically sterile then use of an acceptable form of contraception&#xD;
                  (condom) from the time of randomization through 30 days following the last dose&#xD;
                  of study drug. Male subjects are strongly advised to inform female partners of&#xD;
                  the need for them to use highly effective birth control during this time period.&#xD;
&#xD;
          5. Body mass index (BMI) &lt; 30&#xD;
&#xD;
          6. Clinical laboratory values &lt;2 times the upper limit of normal (ULN) or deemed not&#xD;
             clinically significant by the Investigator.&#xD;
&#xD;
          7. Ability to understand the requirements of the study, provide written informed consent,&#xD;
             abide by the study restrictions, and agree to return for the required assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Human immunodeficiency virus (HIV) infection, or hepatitis or other ongoing infectious&#xD;
             disease&#xD;
&#xD;
          2. Evidence of alcohol abuse (greater than 4 units of alcohol on most days; 1 unit = 1/2&#xD;
             pint of beer, 1 glass of wine or 1 oz. of spirits). Alcohol consumption should be&#xD;
             avoided for at least 24 hours prior to baseline/dosing visit. A positive alcohol&#xD;
             breathalyzer at screening and baseline visit&#xD;
&#xD;
          3. Current abuse of illicit substances, using the Diagnostic and Statistical Manual (DSM)&#xD;
             V definition of substance use disorder.&#xD;
&#xD;
          4. Current cigarette/tobacco smoker or use of other tobacco or nicotine products&#xD;
             including ecigarettes or vaping (if formerly a smoker must not have smoked for at&#xD;
             least one year prior to enrolling in this study). Nonsmoking will be confirmed by&#xD;
             cotinine assay.&#xD;
&#xD;
          5. Currently pregnant, planning to become pregnant during the course of the study, or&#xD;
             nursing mother&#xD;
&#xD;
          6. Impaired renal function (GFR &lt; 90 ml/min)&#xD;
&#xD;
          7. Elevated systolic blood pressure (&gt; 130 mmHg) or diastolic blood pressure (&gt; 80 mmHg)&#xD;
             and/or increased QTc (&gt;450 msec for men or &gt;470 msec for women) or additional risk&#xD;
             factors for Torsades de Pointes including heart failure, hypokalemia, family history&#xD;
             of Long QT Syndrome&#xD;
&#xD;
          8. Type I or Type II diabetes&#xD;
&#xD;
          9. Malignancy in the last 5 years, with the exception of nonmetastatic basal cell or&#xD;
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix&#xD;
&#xD;
         10. Currently taking prescription (except as listed in Section 7.4.1) or over-the-counter&#xD;
             medications including herbal therapies, within 14 days of enrollment into the study.&#xD;
&#xD;
         11. History of allergy or sensitivity, or intolerance to NMDAR ligands including ketamine,&#xD;
             dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone&#xD;
&#xD;
         12. Received another investigational drug or device within 30 days of enrollment in this&#xD;
             study&#xD;
&#xD;
         13. Previously participated in this study&#xD;
&#xD;
         14. Psychiatric disease including major depression, bipolar disorder, anxiety, or&#xD;
             schizophrenia, or other medical condition that, in the opinion of the Investigator,&#xD;
             would interfere with the evaluation of study drug safety&#xD;
&#xD;
         15. For subjects in lumbar catheter Groups (6 and 7) has a history of excessive bleeding&#xD;
             after invasive procedures or surgery or known coagulation or platelet abnormality, or&#xD;
             has been on any blood thinner or medication affecting platelet function, such as&#xD;
             aspirin, nonsteroidal anti-inflammatory medications, corticosteroids (except topical)&#xD;
             or warfarin within the 7 days prior to enrollment, or has known allergy to any&#xD;
             anesthetic agent that may be used for the lumbar puncture.&#xD;
&#xD;
         16. For subjects in lumbar catheter Groups (6 and 7) has a history of infection that&#xD;
             required IV antibiotics within the 45 days or oral antibiotics within 30 days prior to&#xD;
             enrollment, and, at the time of clinic admission, be febrile or have signs/symptoms&#xD;
             consistent with an infection.&#xD;
&#xD;
         17. For subjects in lumbar catheter Groups (6 and 7) has a history of or physical&#xD;
             examination evidence of a lumbar spine abnormality that may preclude placement of a&#xD;
             spinal catheter, presence of intraspinal shunt devices (e.g. ventriculoperitoneal&#xD;
             shunt), or history of elevated intracranial pressure, normal pressure hydrocephalus,&#xD;
             or other neurological condition that in the opinion of the Investigator precludes safe&#xD;
             study participation.&#xD;
&#xD;
         18. In the opinion of the Investigator, the Safety Monitor, or the Sponsor Study Monitor,&#xD;
             has a history of severe renal or hepatic impairment, severe active hepatic disease, or&#xD;
             other clinically significant medical condition that may preclude safe study&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Burch, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gate Neurosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magdy Shenouda, MD</last_name>
    <phone>212-994-4569</phone>
    <email>mshenouda@clinilabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdy Shenouda, MD</last_name>
      <phone>212-994-4569</phone>
      <email>mshenouda@clinilabs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 31, 2020</study_first_submitted>
  <study_first_submitted_qc>October 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Excessive Sleepiness</keyword>
  <keyword>Metabotropic Glutamate Type 2/3 Receptor Antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleepiness</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

